Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30648762 | 0.80 | ALDH1A1 (0.33) | ALDH1A1CYP1A2 | |
| SCHEMBL21608331 | 0.80 | ACHE (0.36) | — | |
| SCHEMBL26640695 | 0.80 | ALDH1A1 (0.33) | ALDH1A1CYP1A2 | |
| SCHEMBL16077531 | 0.79 | ALDH1A1 (0.33) | ALDH1A1CYP1A2 | |
| SCHEMBL28434013 | 0.73 | — | — | |
| SCHEMBL21652657 | 0.72 | ACHE (0.42) | ALDH1A1CYP1A2CCR1CCR5CCR8 | |
| SCHEMBL15308536 | 0.71 | CCR1 (0.35) | CCR1CCR5CCR8ADRA2AADRA2C | |
| SCHEMBL23790731 | 0.69 | MAP3K14 (0.45) | CCR1CCR5CCR8 | |
| SCHEMBL21334405 | 0.69 | MAP4K1 (0.46) | — | |
| SCHEMBL27371391 | 0.68 | GRM5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ALDH1A1 2724/4885CYP1A2 2524/4885CCR1 2147/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ALDH1A1 2724/4885CYP1A2 2524/4885CCR1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.